局部晚期咽癌与喉癌:术后辅助放疗对比根治性放疗的倾向评分匹配分析
本研究回顾性纳入309例局部晚期口咽、下咽或喉鳞状细胞癌患者,以T分期、N分期和诊断年龄构建倾向评分,按1:1最近邻匹配(卡钳值2%)得到61对患者。匹配后两种策略总生存无统计学差异(p=0.70),术后辅助放疗组在无进展生存(中位81.0 vs 43.4个月,p=0.09)和局部区域无复发生存(p=0.08)上呈数值优势但未达统计学显著;淋巴水肿在辅助放疗组更常见(33% vs 13%,p=0.017)。
要点
- 匹配后术后辅助放疗与根治性放疗总生存相当(p=0.70),支持个体化多学科选择。
- 无进展生存与局部区域无复发生存数值上偏向辅助放疗,但均未达统计学显著。
- 淋巴水肿是唯一显著更常见的毒性(33% vs 13%,p=0.017)。
核心结论
- 在倾向评分匹配后,原发手术加辅助放疗与根治性放疗在局部晚期咽癌和喉癌患者中取得可比的总生存。
- 手术加辅助放疗策略显示出疾病控制与局部控制改善的趋势,但差异无统计学意义。
- 研究结果支持个体化的多学科治疗选择,仍需前瞻性对照研究验证。
研究设计与样本
- 单中心回顾性分析,纳入309例局部晚期口咽、下咽或喉鳞状细胞癌患者。
- 倾向评分由包含T分期、N分期和诊断年龄的多变量逻辑回归模型生成。
- 采用1:1最近邻匹配、卡钳值2%,得到61对分别接受原发手术加辅助放疗或根治性放疗的患者。
- 生存分析采用Kaplan-Meier法和log-rank检验,匹配后另用多变量Cox回归校正既往恶性肿瘤的不均衡。
主要发现
- 匹配后两组各61例,匹配变量的基线特征均衡性改善。
- 中位总生存在手术加辅助放疗组为81个月,根治性放疗组未达到,组间无统计学显著差异(p=0.70)。
- 无进展生存中位值为81.0个月对比43.4个月(p=0.09),局部区域无复发生存p=0.08,均未达统计学显著。
- 淋巴水肿是唯一显著更常见的毒性(33% vs 13%,p=0.017),其他治疗相关毒性发生率相当。
- 校正既往恶性肿瘤的多变量分析确认治疗方式与各项生存之间无显著关联。
关键数值与推荐
- 倾向评分匹配卡钳值为2%,匹配后每组61例。
- 总生存组间比较p=0.70;无进展生存中位81.0 vs 43.4个月,p=0.09;局部区域无复发生存p=0.08。
- 淋巴水肿发生率33% vs 13%,p=0.017。
临床怎么用
- 对于局部晚期咽癌和喉癌,术后辅助放疗与根治性放疗的总生存相当,可结合患者情况个体化多学科决策。
- 选择术后辅助放疗策略时需关注淋巴水肿风险(本组33% vs 13%)。
- 疾病控制方面的数值趋势可作参考,但不应据此单独改变治疗强度,仍需前瞻性研究证实。
局限性
- 为单中心回顾性分析,即使经倾向评分匹配仍可能存在未测量混杂。
- 匹配后样本量较小(每组61例),可能不足以检出统计学显著差异。
- 匹配仅纳入T分期、N分期和诊断年龄,匹配后仍需校正既往恶性肿瘤的不均衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aim: Locally advanced squamous cell carcinoma (SCC) of the pharynx and larynx is commonly treated with either primary surgery followed by adjuvant radiotherapy (RT) or definitive RT with or without concurrent systemic therapy. Comparative outcome data between these treatment strategies remain limited because retrospective analyses are frequently affected by treatment-selection bias. This study compared oncologic outcomes between primary surgery followed by adjuvant RT and definitive RT using propensity score matching to reduce baseline confounding. Methods: A retrospective analysis was performed on 309 patients with locally advanced SCC of the oropharynx, hypopharynx, or larynx treated at our center. Propensity scores were generated using a multivariable logistic regression model including T stage, N stage, and age at diagnosis. One-to-one nearest-neighbor matching with a caliper of 2% resulted in 61 matched patient pairs treated with primary surgery followed by adjuvant RT or definitive RT. Survival outcomes were analyzed using the Kaplan-Meier method and compared using log-rank tests. Multivariable Cox regression analyses were performed to account for imbalances in previous malignancies after matching. Results: After propensity score matching, 61 patients treated with primary surgery followed by adjuvant RT and 61 patients treated with definitive RT were included, with improved balanced baseline characteristics for the matching variables. Median OS was 81 months in the surgery followed by adjuvant RT group and was not reached in the definitive RT group, with no statistically significant difference between groups (p = 0.70). Numerical differences favored adjuvant RT for progression-free survival (median PFS: 81.0 vs. 43.4 months; p = 0.09) and loco-regional recurrence-free survival (p = 0.08), although these differences were not statistically significant. Lymphedema was the only toxicity significantly more frequent in the adjuvant RT cohort (33% vs. 13%, p = 0.017), while rates of other treatment-related toxicities were comparable. Multivariable analyses adjusted for previous malignancies confirmed the absence of significant associations between treatment modality and survivals. Conclusion: Primary surgery followed by adjuvant RT and definitive RT achieved comparable overall survival in patients with locally advanced SCC of the pharynx and larynx after propensity score matching. However, the surgery plus adjuvant RT strategy demonstrated trends toward improved disease control and local control. These findings support individualized multidisciplinary treatment selection while prospective comparative studies remain warranted.
引用
- Agolli L, Mici E, Langer C, et al. Surgery followed by adjuvant radiotherapy versus definitive radiotherapy for locally advanced squamous cell carcinoma of the pharynx and larynx: a propensity score-matched analysis. Clin Transl Radiat Oncol. 2026. PMID: 42828129. doi:10.1016/j.ctro.2026.101288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。